Diamyd Medical accelerates primary efficacy readout by 9 months in type 1 diabetes Phase 3 trial following FDA alignment and guidance
STOCKHOLM, Dec. 29, 2025 /PRNewswire/ — Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to…
